A Study of TACE in Combination With SHR-8068, Adebrelimab, and Bevacizumab Versus TACE in Participants With Incurable Hepatocellular Carcinoma
A Phase III, Randomized, Double-blind, Multicenter Study of SHR-8068 and Adebrelimab Plus Bevacizumab in Combination With TACE in Participants With Incurable Hepatocellular Carcinoma
This is a multicenter, Phase 3 clinical trial to evaluate the efficacy and safety of SHR-8068, Adebrelimab, and Bevacizumab and TACE versus Placebo with TACE in incurable hepatocellular carcinoma.
Participants will continue treatment until disease progresses, intolerable toxicity, withdrawal of informed consent, loss of follow-up, death, or other circumstances that require termination of treatment, whichever occurs first.
調査の概要
状態
条件
研究の種類
入学 (推定)
段階
- フェーズ 3
連絡先と場所
研究連絡先
- 名前:Junqin Yang
- 電話番号:+86-0518-82342973
- メール:junqin.yang@hengrui.com
研究連絡先のバックアップ
- 名前:Huan Wang
- 電話番号:+86-0518-82342973
- メール:huan.wang.hw396@hengrui.com
研究場所
-
-
Jiangsu
-
Nanjing、Jiangsu、中国、210009
- Zhongda Hospital Southeast University
-
主任研究者:
- Gaojun Teng
-
コンタクト:
- Gaojun Teng
- 電話番号:+86-025-83272084
- メール:gjteng@seu.edu.cn
-
-
Shanghai Municipality
-
Shanghai、Shanghai Municipality、中国、200032
- Zhongshan Hospital, Fudan University
-
主任研究者:
- Jia Fan
-
コンタクト:
- Jia Fan
- 電話番号:+86-021-64041990
- メール:fan.jia@zs-hospital.sh.cn
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- Age 18-75 years old, male or female;
- Diagnosis confirmed HCC by pathologically or clinically;
- At least one measurable lesion;
- Child-Pugh liver function grade A;
- ECOG-PS score: 0 or 1;
- Eligible for TACE treatment as assessed by the investigator;
- Participants with HBV or HCV infection must be on and remain on standard antiviral therapy throughout the study period;
- Consent to contraception.
Exclusion Criteria:
- Fibrolamellar hepatocellular carcinoma, sarcomatoid hepatocellular carcinoma or mixed cholangiocarcinoma / hepatocellular carcinoma; Participants with other malignancies currently or within the past 5 years;
- Participants with any active, known or suspected autoimmune disorder;
- Participants with hypertension which cannot be well controlled by antihypertensives;
- Uncontrolled cardiac diseases or symptoms;
- Participants with hepatic encephalopathy;
- Prior esophageal and/or gastric varices bleeding within 6 months prior to initiation of study treatment;
- History of gastrointestinal perforation and/or fistula;
- Participants with other potential factors that may affect the study results.
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:4倍
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:Treatment group A
SHR-8068 + Adebrelimab + Bevacizumab + Transarterial Chemoembolization (TACE) |
SHR-8068 + Adebrelimab + Bevacizumab, intravenous infusion, Transarterial Chemoembolization (TACE) |
|
アクティブコンパレータ:Treatment group B
SHR-8068 Placebo + Adebrelimab Placebo + Bevacizumab Placebo + Transarterial Chemoembolization (TACE) |
SHR-8068 Placebo + Adebrelimab Placebo + Bevacizumab Placebo, intravenous infusion, Transarterial Chemoembolization(TACE) |
|
実験的:Treatment group C
SHR-8068 Placebo + Adebrelimab + Bevacizumab + Transarterial Chemoembolization (TACE) |
SHR-8068 Placebo + Adebrelimab + Bevacizumab, intravenous infusion, Transarterial Chemoembolization (TACE) |
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
時間枠 |
|---|---|
|
Progression-free survival (PFS) assessed by investigator
時間枠:Until progression, assessed up to approximately 2 years.
|
Until progression, assessed up to approximately 2 years.
|
二次結果の測定
結果測定 |
時間枠 |
|---|---|
|
Adverse events (AEs)
時間枠:Until study completion, assessed up to approximately 2 years.
|
Until study completion, assessed up to approximately 2 years.
|
|
Serious adverse events (SAEs)
時間枠:Until study completion, assessed up to approximately 3 years.
|
Until study completion, assessed up to approximately 3 years.
|
|
Progression-free survival (PFS) assessed by Blinded Independent Review Committee (BIRC)
時間枠:Until progression, assessed up to approximately 2 years.
|
Until progression, assessed up to approximately 2 years.
|
|
Overall survival (OS)
時間枠:Until study completion, assessed up to approximately 2 years.
|
Until study completion, assessed up to approximately 2 years.
|
|
Objective response rate (ORR)
時間枠:Until study completion, assessed up to approximately 2 years.
|
Until study completion, assessed up to approximately 2 years.
|
|
Disease control rate (DCR)
時間枠:Until study completion, assessed up to approximately 2 years.
|
Until study completion, assessed up to approximately 2 years.
|
|
Duration of objective tumor response (DoR)
時間枠:Until study completion, assessed up to approximately 2 years.
|
Until study completion, assessed up to approximately 2 years.
|
|
Pharmacokinetics parameters of SHR-8068 and Adebrelimab: serum concentration
時間枠:Approximately 90 days post-last dose.
|
Approximately 90 days post-last dose.
|
|
Immunogenicity indicators of SHR-8068 and Adebrelimab: drug resistant antibody (ADA) and neutralizing antibody (NAb)
時間枠:Approximately 90 days post-last dose.
|
Approximately 90 days post-last dose.
|
協力者と研究者
研究記録日
主要日程の研究
研究開始 (推定)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
その他の研究ID番号
- SHR-8068-305
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。